GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Days Sales Outstanding

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Days Sales Outstanding : 13.33 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Days Sales Outstanding?

Sichuan Kelun-Biotech Biopharmaceutical Co's average Accounts Receivable for the six months ended in Dec. 2024 was HK$43 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's Revenue for the six months ended in Dec. 2024 was HK$587 Mil. Hence, Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding for the six months ended in Dec. 2024 was 13.33.

The historical rank and industry rank for Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding or its related term are showing as below:

HKSE:06990' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.07   Med: 1.65   Max: 10.92
Current: 7.55

During the past 4 years, Sichuan Kelun-Biotech Biopharmaceutical Co's highest Days Sales Outstanding was 10.92. The lowest was 0.07. And the median was 1.65.

HKSE:06990's Days Sales Outstanding is ranked better than
97.06% of 851 companies
in the Biotechnology industry
Industry Median: 72.85 vs HKSE:06990: 7.55

Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding increased from Dec. 2023 (0.00) to Dec. 2024 (13.33).

Sichuan Kelun-Biotech Biopharmaceutical Co Days Sales Outstanding Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Days Sales Outstanding Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
1.65 0.07 - 10.92

Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Days Sales Outstanding Get a 7-Day Free Trial - - - 2.95 13.33

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding falls into.


;
;

Sichuan Kelun-Biotech Biopharmaceutical Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0 + 61.756) / 1 ) / 2063.858*365
=61.756 / 2063.858*365
=10.92

Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding (Q: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2024 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (24.092 + 61.756) / 2 ) / 587.491*365 / 2
=42.924 / 587.491*365 / 2
=13.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Sichuan Kelun-Biotech Biopharmaceutical Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Days Sales Outstanding
Comparable Companies
HKSE:09926 HKSE:01177 HKSE:01801 HKSE:01877 HKSE:01530 HKSE:01548 HKSE:02269 HKSE:09995 HKSE:02696 HKSE:09969 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Website
http://www.kelun-biotech.com
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Executives
Liu Gexin 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Merck & Co., Inc. 2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc 2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Zhou Quan 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p. 2201 Interest of corporation controlled by you
Victory Rhythm Limited 2201 Interest of corporation controlled by you
Wealthy Linkage Limited 2101 Beneficial owner
Ho Chi Sing 2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co Headlines

No Headlines